Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):458–462. doi: 10.1054/bjoc.2000.1295

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

C Kollmannsberger 1, D Quietzsch 2, C Haag 3, T Lingenfelser 4, M Schroeder 5, J T Hartmann 1, W Baronius 2, V Hempel 2, M Clemens 6, L Kanz 1, C Bokemeyer 1
PMCID: PMC2374647  PMID: 10945491

Abstract

To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts (28 male and 17 female) with a median age of 60 years (range 35–74) were enrolled. 5-FU 2 g/m2was given weekly over 24 h i.v. preceded by folinic acid 500 mg/m2as a 2 h infusion. Paclitaxel 175 mg/m2was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m2as 1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median of 3 cycles (range 1–4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11%) obtained a CR and 18 pts (40%) a PR (ORR 51%; 95% Cl: 35.8–66.3%). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour. Nine pts (20%) had stable disease. Thirteen pts (29%) were considered to have failed treatment, 8 pts (18%) due to progressive disease and 5 pts (11%) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall survival times were 9 months (range 1–36+) and 14 months (range 2–36+), respectively. Neutropenia WHO III°/IV° occurred in 7 pts (15%) with only 1 pt having grade IV. Additional non-haematologic WHO III°/IV° toxicities included nausea/vomiting in 5 (11%), alopecia in 22 (49%), and diarrhoea in 1 patient each (2%). Dose reductions or treatment delays were necessary in 8 pts (17%), mainly due to neutropenia. All pts were treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment. © 2000 Cancer Research Campaign

Keywords: gastric cancer, metastatic, chemotherapy, paclitaxel, continuous infusion

Full Text

The Full Text of this article is available as a PDF (68.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajani J. A., Fairweather J., Dumas P., Patt Y. Z., Pazdur R., Mansfield P. F. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug;4(4):269–274. [PubMed] [Google Scholar]
  2. Ardalan B., Chua L., Tian E. M., Reddy R., Sridhar K., Benedetto P., Richman S., Legaspi A., Waldman S., Morrell L. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol. 1991 Apr;9(4):625–630. doi: 10.1200/JCO.1991.9.4.625. [DOI] [PubMed] [Google Scholar]
  3. Bokemeyer C., Hartmann J. T., Lampe C. S., Clemens M. R., Quietzsch D., Forkmann L., Kanz L. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19–96-S19-100. [PubMed] [Google Scholar]
  4. Bokemeyer C., Lampe C. S., Clemens M. R., Hartmann J. T., Quietzsch D., Forkmann L., Kollmannsberger C., Kanz L. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs. 1997 Apr;8(4):396–399. doi: 10.1097/00001813-199704000-00014. [DOI] [PubMed] [Google Scholar]
  5. Cascinu S., Ficarelli R., Safi M. A., Graziano F., Catalano G., Cellerino R. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer. 1997 Sep;33(10):1699–1702. doi: 10.1016/s0959-8049(97)00134-2. [DOI] [PubMed] [Google Scholar]
  6. Cascinu S., Graziano F., Cardarelli N., Marcellini M., Giordani P., Menichetti E. T., Catalano G. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998 Apr;9(4):307–310. doi: 10.1097/00001813-199804000-00003. [DOI] [PubMed] [Google Scholar]
  7. Chang Y. F., Li L. L., Wu C. W., Liu T. Y., Lui W. Y., P'eng F. K., Chi C. W. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 1996 Jan 1;77(1):14–18. doi: 10.1002/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  8. Findlay M., Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev. 1993 Jan;19(1):29–44. doi: 10.1016/0305-7372(93)90025-m. [DOI] [PubMed] [Google Scholar]
  9. Glimelius B., Ekström K., Hoffman K., Graf W., Sjödén P. O., Haglund U., Svensson C., Enander L. K., Linné T., Sellström H. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163–168. doi: 10.1023/a:1008243606668. [DOI] [PubMed] [Google Scholar]
  10. Hartmann J. T., Quietzsch D., Daikeler T., Kollmannsberger C., Mayer F., Kanz L., Bokemeyer C. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs. 1999 Sep;10(8):729–733. doi: 10.1097/00001813-199909000-00006. [DOI] [PubMed] [Google Scholar]
  11. Ilson D. H., Ajani J., Bhalla K., Forastiere A., Huang Y., Patel P., Martin L., Donegan J., Pazdur R., Reed C. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May;16(5):1826–1834. doi: 10.1200/JCO.1998.16.5.1826. [DOI] [PubMed] [Google Scholar]
  12. Kano Y., Akutsu M., Tsunoda S., Ando J., Matsui J., Suzuki K., Ikeda T., Inoue Y., Adachi K. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996 Sep;74(5):704–710. doi: 10.1038/bjc.1996.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kelsen D., Atiq O. T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Heelan R., Lightdale C., Vinciguerra V., Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541–548. doi: 10.1200/JCO.1992.10.4.541. [DOI] [PubMed] [Google Scholar]
  14. Kim N. K., Park Y. S., Heo D. S., Suh C., Kim S. Y., Park K. C., Kang Y. K., Shin D. B., Kim H. T., Kim H. J. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813–3818. doi: 10.1002/1097-0142(19930615)71:12<3813::aid-cncr2820711205>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  15. Kim Y. H., Shin S. W., Kim B. S., Kim J. H., Kim J. G., Mok Y. J., Kim C. S., Rhyu H. S., Hyun J. H., Kim J. S. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999 Jan 15;85(2):295–301. [PubMed] [Google Scholar]
  16. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Murad AM. Chemotherapy for Advanced Gastric Cancer: Focus on New Agents and Combinations. Cancer Control. 1999 Jul;6(4):361–368. doi: 10.1177/107327489900600406. [DOI] [PubMed] [Google Scholar]
  18. Okada Y., Anai H., Hattori T., Maehara Y., Nishimura J., Sugimachi K., Nawata H. Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. Anticancer Drugs. 1991 Oct;2(5):453–456. doi: 10.1097/00001813-199110000-00003. [DOI] [PubMed] [Google Scholar]
  19. Preusser P., Wilke H., Achterrath W., Fink U., Lenaz L., Heinicke A., Meyer J., Meyer H. J., Buente H. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989 Sep;7(9):1310–1317. doi: 10.1200/JCO.1989.7.9.1310. [DOI] [PubMed] [Google Scholar]
  20. Pyrhönen S., Kuitunen T., Nyandoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587–591. doi: 10.1038/bjc.1995.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rougier P., Ducreux M., Mahjoubi M., Pignon J. P., Bellefqih S., Oliveira J., Bognel C., Lasser P., Ychou M., Elias D. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer. 1994;30A(9):1263–1269. doi: 10.1016/0959-8049(94)90170-8. [DOI] [PubMed] [Google Scholar]
  22. Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. doi: 10.1093/jnci/82.15.1247. [DOI] [PubMed] [Google Scholar]
  23. Scanlon K. J., Newman E. M., Lu Y., Priest D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923–8925. doi: 10.1073/pnas.83.23.8923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schabel F. M., Jr, Trader M. W., Laster W. R., Jr, Corbett T. H., Griswold D. P., Jr cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459–1473. [PubMed] [Google Scholar]
  25. Schipper D. L., Wagener D. J. Chemotherapy of gastric cancer. Anticancer Drugs. 1996 Feb;7(2):137–149. doi: 10.1097/00001813-199602000-00001. [DOI] [PubMed] [Google Scholar]
  26. Vanhoefer U., Harstrick A., Wilke H., Schleucher N., Walles H., Schröder J., Seeber S. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer. 1995;31A(1):92–97. doi: 10.1016/0959-8049(94)00440-g. [DOI] [PubMed] [Google Scholar]
  27. Vanhoefer U., Wilke H., Weh H. J., Clemens M., Harstrick A., Stahl M., Hossfeld D. K., Seeber S. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol. 1994 Nov;5(9):850–851. doi: 10.1093/oxfordjournals.annonc.a059017. [DOI] [PubMed] [Google Scholar]
  28. Waters J. S., Norman A., Cunningham D., Scarffe J. H., Webb A., Harper P., Joffe J. K., Mackean M., Mansi J., Leahy M. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269–272. doi: 10.1038/sj.bjc.6690350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]
  30. Wilke H., Korn M., Vanhöfer U., Fink U., Stahl M., Preusser P., Köhne C., Klassen U., Harstrick A., Schmoll H. J. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother. 1996 Summer;6(3):123–126. [PubMed] [Google Scholar]
  31. Wilke H., Preusser P., Fink U., Achterrath W., Lenaz L., Stahl M., Schober C., Link H., Meyer H. J., Lucke B. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs. 1990 Feb;8(1):65–70. doi: 10.1007/BF00216926. [DOI] [PubMed] [Google Scholar]
  32. Wils J. The treatment of advanced gastric cancer. Semin Oncol. 1996 Jun;23(3):397–406. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES